Systematic review with meta-analysis: the comparative effectiveness of aspirin vs. screening for colorectal cancer prevention

Alimentary Pharmacology and Therapeutics

Volumn 45, Issue 2, 2017, Pages 193-204

  Emilsson, L ^a,b,e   Holme, O ^a,c   Bretthauer, M ^a,d,e   Cook, N R ^e,f   Buring, J E ^e,f   Loberg M ^a,d   Adami, H O ^e,g   Sesso, H D ^e,f   Gaziano, M J ^f   Kalager, M ^a,e,h  

^a UNIVERSITY OF OSLO   (Norway)

^b Primary Care Research Unit   (Sweden)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d Sørlandet Hospital   (Norway)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g KAROLINSKA INSTITUTE   (Sweden)

^h TELEMARK HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; GUAIAC;

CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CLINICAL EFFECTIVENESS; COLORECTAL CANCER; COMPARATIVE EFFECTIVENESS; DRUG EFFICACY; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; OCCULT BLOOD TEST; PRIORITY JOURNAL; REVIEW; SIGMOIDOSCOPY; SYSTEMATIC REVIEW; COLORECTAL NEOPLASMS; EARLY CANCER DIAGNOSIS; INCIDENCE; MASS SCREENING; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ASPIRIN; COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; HUMANS; INCIDENCE; MASS SCREENING; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85002194712     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13857     Document Type: Review

References (46)

1. Holme O, Bretthauer M, Fretheim A, Odgaard-Jensen J, Hoff G. Flexible sigmoidoscopy versus faecal occult blood testing for colorectal cancer screening in asymptomatic individuals. Cochrane Database Syst Rev 2013; 9: CD009259.
2. Sutcliffe P, Connock M, Gurung T, et al. Aspirin for prophylactic use in the primary prevention of cardiovascular disease and cancer: a systematic review and overview of reviews. Health Technol Assess 2013; 17: 1–253.
3. Hassan C, Rex DK, Cooper GS, Zullo A, Launois R, Benamouzig R. Primary prevention of colorectal cancer with low-dose aspirin in combination with endoscopy: a cost-effectiveness analysis. Gut 2011; 61: 1172–9.
4. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Available at: www.cochrane-handbook.org: Wiley/Blackwell; 2011.
5. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6: e1000097.
6. Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 2015; 162: 777–84.
7. Rothwell PM, Wilson M, Elwin CE, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 2010; 376: 1741–50.
8. Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology 2008; 134: 1570–95.
9. Farrell B, Godwin J, Richards S, Warlow C. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 1991; 54: 1044–54.
10. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework. Lancet 1998; 351: 233–41.
11. Peto R, Gray R, Collins R, et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed) 1988; 296: 313–6.
12. Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. The SALT Collaborative Group. Lancet 1991; 338: 1345–9.
13. Flossmann E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 2007; 369: 1603–13.
14. Gann PH, Manson JE, Glynn RJ, Buring JE, Hennekens CH. Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst 1993; 85: 1220–4.
15. Cook NR, Lee IM, Zhang SM, Moorthy MV, Buring JE. Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Ann Intern Med 2013; 159: 77–85.
16. Cook N. In: Emilsson L, ed. CRC mortality data from WHS. 2015.
17. Sesso HD. In: Emilsson L, ed. Frequency of colorectal cancer by aspirin. 2015.
18. Wells GA, Sultan SA, Chen L, Khan M, Coyle D. Indirect Evidence: Indirect Treatment Comparisons in Meta-analysis. Ottawa: Canadian Agency for Drugs and Technologies in Health, 2009.
19. Chaimani A, Higgins JPT, Mavridis D, Spyridonos P, Salanti G. Graphical tools for network meta-analysis in STATA. PLoS ONE [Electronic Resource] 2013; 8: e76654.
20. White IR, Barrett JK, Jackson D, Higgins JP. Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression. Res Synth Methods 2012; 3: 111–25.
21. White IR. Multivariate random-effects meta-analysis. Stata J 2009; 9: 40–56.
22. White IR. Multivariate random-effects meta-regression: Updates to mvmeta. Stata J 2011; 11: 255–70.
23. Higgins JP, Thompson SG, Spiegelhalter DJ. A re-evaluation of random-effects meta-analysis. J R Stat Soc Ser A Stat Soc 2009; 172: 137–59.
24. Nikolakopoulou A, Chaimani A, Veroniki AA, Vasiliadis HS, Schmid CH, Salanti G. Characteristics of networks of interventions: a description of a database of 186 published networks. PLoS ONE [Electronic Resource] 2014; 9: e86754.
25. Salanti G, Higgins JP, Ades AE, Ioannidis JP. Evaluation of networks of randomized trials. Stat Methods Med Res 2008; 17: 279–301.
26. Segnan N, Armaroli P, Bonelli L, et al. Once-only sigmoidoscopy in colorectal cancer screening: follow-up findings of the Italian randomized controlled trial—SCORE. J Natl Cancer Inst 2011; 103: 1310–22.
27. Scholefield JH, Moss SM, Mangham CM, Whynes DK, Hardcastle JD. Nottingham trial of faecal occult blood testing for colorectal cancer: a 20-year follow-up. Gut 2012; 61: 1036–40.
28. Schoen RE, Pinsky PF, Weissfeld JL, et al. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med 2012; 366: 2345–57.
29. Lin JS, Piper MA, Perdue LA, et al. Screening for Colorectal cancer: updated evidence report and systematic review for the US preventive services task force. JAMA 2016; 315: 2576–94.
30. Chubak J, Kamineni A, Buist DSM, Anderson ML, Whitlock EP, 2015.
31. Stegeman I, Bossuyt PM, Yu T, Boyd C, Puhan MA. Aspirin for primary prevention of cardiovascular disease and cancer. A benefit and harm analysis. PLoS ONE 2015; 10: e0127194.
32. Van Kruijsdijk RCM, Visseren FLJ, Ridker PM, et al. Individualised prediction of alternate-day aspirin treatment effects on the combined risk of cancer, cardiovascular disease and gastrointestinal bleeding in healthy women. Heart 2015; 101: 369–76.
33. Puhan MA, Yu T, Stegeman I, Varadhan R, Singh S, Boyd CM. Benefit-harm analysis and charts for individualized and preference-sensitive prevention: example of low dose aspirin for primary prevention of cardiovascular disease and cancer. BMC Med 2015; 13: 250.
34. Berstad P, Loberg M, Larsen IK, et al. Long-term lifestyle changes after colorectal cancer screening: randomised controlled trial. Gut 2015; 64: 1268–76.
35. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011; 377: 31–41.
36. Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol 2012; 13: 518–27.
37. Thiis-Evensen E, Kalager M, Bretthauer M, Hoff G. Long-term effectiveness of endoscopic screening on incidence and mortality of colorectal cancer: a randomized trial. United European Gastroenterol J 2013; 1: 162–8.
38. Holme O, Loberg M, Kalager M, et al. Effect of flexible sigmoidoscopy screening on colorectal cancer incidence and mortality: a randomized clinical trial. JAMA 2014; 312: 606–15.
39. Atkin WS, Edwards R, Kralj-Hans I, et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 2010; 375: 1624–33.
40. Mandel JS, Church TR, Bond JH, et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med 2000; 343: 1603–7.
41. Shaukat A, Mongin SJ, Geisser MS, et al. Long-term mortality after screening for colorectal cancer. N Engl J Med 2013; 369: 1106–14.
42. Lindholm E, Brevinge H, Haglind E. Survival benefit in a randomized clinical trial of faecal occult blood screening for colorectal cancer. Br J Surg 2008; 95: 1029–36.
43. Kronborg O, Jørgensen OD, Fenger C, Rasmussen M. Randomized study of biennial screening with a faecal occult blood test: results after nine screening rounds. Scand J Gastroenterol 2004; 39: 846–51.
44. Rexrode KM, Lee IM, Cook NR, Hennekens CH, Buring JE. Baseline characteristics of participants in the Women's Health Study. J Womens Health Gend Based Med 2000; 9: 19–27.
45. Cook NR, Lee IM, Gaziano JM, et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA 2005; 294: 47–55.
46. Findings from the aspirin component of the ongoing Physicians’ Health Study. N Engl J Med 1988; 318: 262–4.